| General Information | |
|---|---|
| ZINC ID | ZINC000064511845 |
| Molecular Weight (Da) | 565 |
| SMILES | Cc1c(C(=O)NCCCCCN(C)CCCCCN)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C28Cl3N5O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 156.41 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 14 |
| Heavy Atoms | 37 |
| LogP | 7.156 |
| Activity (Ki) in nM | 89.1251 |
| Polar Surface Area (PSA) | 76.18 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | + |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.01035523 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.43 |
| Ilogp | 5.05 |
| Xlogp3 | 6.65 |
| Wlogp | 6.77 |
| Mlogp | 4.64 |
| Silicos-it log p | 7 |
| Consensus log p | 6.02 |
| Esol log s | -6.88 |
| Esol solubility (mg/ml) | 0.0000741 |
| Esol solubility (mol/l) | 0.00000013 |
| Esol class | Poorly sol |
| Ali log s | -8.05 |
| Ali solubility (mg/ml) | 0.00000502 |
| Ali solubility (mol/l) | 8.88E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.84 |
| Silicos-it solubility (mg/ml) | 8.24E-09 |
| Silicos-it solubility (mol/l) | 1.46E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.02 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 4 |
| Veber number of violations | 1 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 4.07 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.374 |
| Logd | 4.152 |
| Logp | 6.01 |
| F (20%) | 0.002 |
| F (30%) | 0.003 |
| Mdck | - |
| Ppb | 93.82% |
| Vdss | 3.09 |
| Fu | 5.04% |
| Cyp1a2-inh | 0.204 |
| Cyp1a2-sub | 0.956 |
| Cyp2c19-inh | 0.771 |
| Cyp2c19-sub | 0.873 |
| Cl | 8.271 |
| T12 | 0.016 |
| H-ht | 0.343 |
| Dili | 0.95 |
| Roa | 0.305 |
| Fdamdd | 0.593 |
| Skinsen | 0.512 |
| Ec | 0.003 |
| Ei | 0.006 |
| Respiratory | 0.535 |
| Bcf | 1.815 |
| Igc50 | 5.29 |
| Lc50 | 6.525 |
| Lc50dm | 6.463 |
| Nr-ar | 0.071 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.747 |
| Nr-aromatase | 0.882 |
| Nr-er | 0.301 |
| Nr-er-lbd | 0.005 |
| Nr-ppar-gamma | 0.027 |
| Sr-are | 0.785 |
| Sr-atad5 | 0.011 |
| Sr-hse | 0.15 |
| Sr-mmp | 0.676 |
| Sr-p53 | 0.869 |
| Vol | 552.854 |
| Dense | 1.019 |
| Flex | 0.833 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.212 |
| Synth | 2.583 |
| Fsp3 | 0.429 |
| Mce-18 | 20 |
| Natural product-likeness | -1.125 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |